QuBind

Executive Summary

QuBind is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, founded in 2018 with a focus on developing small molecule inhibitors targeting protein-protein interactions (PPIs) for oncology. By addressing historically 'undruggable' targets, QuBind aims to create novel cancer therapeutics. The company has not yet disclosed specific pipeline programs, financing rounds, or clinical milestones, suggesting it remains in early discovery or lead optimization phases. Given the challenging nature of PPI drug discovery and the competitive landscape, QuBind's progress will depend on advancing its proprietary platform and securing partnerships or funding to move toward the clinic.

Upcoming Catalysts (preview)

• H2 2026Lead optimization updates or preclinical data release30% success
• H1 2027Series A or seed financing round50% success
• TBDResearch collaboration or licensing deal with larger pharma20% success